ETNB 89bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ETNB

Price (delayed)

$8.86

Market cap

$828.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2

Enterprise value

$539.37M

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is ...

Highlights
89bio's quick ratio has soared by 156% YoY and by 10% from the previous quarter
The equity is up by 31% since the previous quarter
ETNB's EPS is up by 32% year-on-year but it is down by 10% since the previous quarter
The company's net income fell by 39% YoY and by 12% QoQ
89bio's debt has increased by 32% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.89bio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ETNB
Market
Shares outstanding
93.5M
Market cap
$828.42M
Enterprise value
$539.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$133.53M
EBITDA
-$133.26M
Free cash flow
-$129.19M
Per share
EPS
-$2
Free cash flow per share
-$1.82
Book value per share
$7.09
Revenue per share
$0
TBVPS
$8.38
Balance sheet
Total assets
$596.27M
Total liabilities
$59.96M
Debt
$27.11M
Equity
$536.31M
Working capital
$563.92M
Liquidity
Debt to equity
0.05
Current ratio
20.04
Quick ratio
19.55
Net debt/EBITDA
2.17
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-27.8%
Return on equity
-31%
Return on invested capital
-61%
Return on capital employed
-23.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ETNB stock price

How has the 89bio stock price performed over time
Intraday
1.26%
1 week
7.39%
1 month
-16.26%
1 year
-43.99%
YTD
-20.68%
QTD
-23.88%

Financial performance

How have 89bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$151.2M
Net income
-$142.19M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 48% YoY and by 12% QoQ
The company's net income fell by 39% YoY and by 12% QoQ

Growth

What is 89bio's growth rate over time

Valuation

What is 89bio stock price valuation
P/E
N/A
P/B
1.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ETNB's EPS is up by 32% year-on-year but it is down by 10% since the previous quarter
The stock's price to book (P/B) is 50% less than its 5-year quarterly average of 2.5 and 46% less than its last 4 quarters average of 2.3
The equity is up by 31% since the previous quarter

Efficiency

How efficient is 89bio business performance
89bio's return on equity has surged by 63% YoY and by 11% QoQ
ETNB's return on assets has surged by 54% year-on-year and by 10% since the previous quarter
The ROIC has grown by 37% YoY and by 8% from the previous quarter

Dividends

What is ETNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ETNB.

Financial health

How did 89bio financials performed over time
89bio's quick ratio has soared by 156% YoY and by 10% from the previous quarter
ETNB's current ratio has surged by 151% year-on-year and by 10% since the previous quarter
89bio's debt is 95% lower than its equity
ETNB's debt to equity has plunged by 64% YoY and by 17% from the previous quarter
89bio's debt has increased by 32% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.